Matrix Metalloproteinase 2
Research News and Information

Sunday, November 22, 2009

CXCL14 inhibits trophoblast outgrowth via a paracrine/autocrine manner during early pregnancy in mice.

30 Oct 2009 CXCL14, a member of chemokine family, was previously known to participate in many pathophysiological events, such as leukocytes recruitment and tumor suppression. However, it remained largely unknown whether CXCL14 is a physiological player during ... Read more...

Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl)methylthiirane and its oxirane analogue.

18 Oct 2009 The inhibition mechanism of matrix metalloproteinase 2 (MMP2) by the selective inhibitor (4-phenoxyphenylsulfonyl)methylthiirane (SB-3CT) and its oxirane analogue is investigated computationally. The inhibition mechanism involves C-H deprotonation ... Read more...

Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo.

3 Oct 2009 Platelet activation at a site of vascular injury is essential for the arrest of bleeding; however, excessive platelet activation at a site of arterial damage can result in the unwarranted formation of arterial thrombi, precipitating acute myocardial ... Read more...

Latest indexed articles for 'Matrix Metalloproteinase 2'

These are the very latest articles for this heading:

• CXCL14 inhibits trophoblast outgrowth via a paracrine/autocrine manner during early pregnancy in mice. 30 Oct 2009
• Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl)methylthiirane and its oxirane analogue. 18 Oct 2009
• Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. 3 Oct 2009
• Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. 3 Oct 2009
• Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. 29 Sep 2009
• Potential role of Notch1 signaling pathway in laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, cell cycle arrest, cell apoptosis, and cell migration. 29 Sep 2009
• Histological and molecular analysis of the biceps tendon long head post-tenotomy. 29 Sep 2009
• Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. 29 Sep 2009
• Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells. 24 Sep 2009
• Direct cancer-stromal interaction increases fibroblast proliferation and enhances invasive properties of scirrhous-type gastric carcinoma cells. 20 Sep 2009
• A novel approach to using matrix metalloproteinases for bladder cancer. 14 Sep 2009
• Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. 13 Sep 2009
• Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. 13 Sep 2009
• Understanding abdominal aortic aneurysm. 8 Sep 2009
• Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. 6 Sep 2009
• Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy. 2 Sep 2009
• Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-beta activation. 31 Aug 2009
• High matrix metalloproteinase activity is a hallmark of periapical granulomas. 30 Aug 2009
• Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas. 30 Aug 2009
• Role of angiotensin II type 1 receptor in cerebral aneurysm formation in rats. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Matrix Metalloproteinase 2'

Definition: A secreted endopeptidase homologous with INTERSTITIAL COLLAGENASE, but which possesses an additional fibronectin-like domain.

Registry Number: EC 3.4.24.24

Descriptor UI: D020778

Alternative terms: Matrix Metalloproteinase 2; Metalloproteinase 2, Matrix; MMP-2 Metalloproteinase; MMP 2 Metalloproteinase; Metalloproteinase, MMP-2; MMP2 Metalloproteinase; Metalloproteinase, MMP2; 72-kDa Type IV Collagenase; 72 kDa Type IV Collagenase; Gelatinase A; Matrix Metalloproteinase-2; 72-kDa Gelatinase; 72 kDa Gelatinase; Gelatinase, 72-kDa;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Tree Number: D08.811.277.656.300.480.205.352; D08.811.277.656.300.480.252.420; D08.811.277.656.300.480.525.700.150; D08.811.277.656.675.374.205.352; D08.811.277.656.675.374.252.420; D08.811.277.656.675.374.525.700.150;

History Note: 2007(2000)

Technical Notes: /antag is permitted but TISSUE INHIBITOR OF METALLOPROTEINASE-2 is available